Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
BEIJING TIDE PHARMACEUTICAL CO., LTD. manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company currently has 4 pending office actions. These actions are distributed among 4 distinct examiners and 3 distinct art units. This indicates that while the company is working with several different examiners, some of those examiners are likely grouped within the same specialized units.
WELLS, LAUREN QUINLAN is the busiest examiner for the portfolio, with 1 busiest examiner pending office action. Since there are 4 pending office actions and 4 distinct examiners, each examiner is handling 1 action. The use of 3 distinct art units for 4 pending actions means that some of the actions are being reviewed within the same administrative group. This distribution requires the company to manage relationships across 4 different examiners while navigating the specific technical standards of 3 different art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 3 (75%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WELLS, LAUREN QUINLAN | 1 | 48.4% | +60.3% |
| ARNOLD, ERNST V | 1 | 48.2% | +12.9% |
| MOU, LIYUAN | 1 | 42.9% | +59.0% |
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +35.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18856731 | EGFR DEGRADATION AGENT | WELLS, LAUREN QUINLAN | — |
| 18710713 | NANOCRYSTALLINE PREPARATION OF ROCK2 INHIBITOR AND PREPARATION METHOD THEREFOR | ARNOLD, ERNST V | — |
| 18691908 | SOLID FORM OF RHO-ASSOCIATED PROTEIN KINASE INHIBITOR OR SOLVATE THEREOF, PREPARATION METHOD AND USE THEREOF | MOU, LIYUAN | — |
| 17607438 | METHOD FOR TREATING COUGH BY USING DIAMINOPYRIMIDINE COMPOUND | PECKHAM, RICHARD GRANT | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1628 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18856731 | EGFR DEGRADATION AGENT | WELLS, LAUREN QUINLAN | — | §102§103§112DP | Non-Final OA | — | Pending | Oct 14, 2024 |
| 18710713 | NANOCRYSTALLINE PREPARATION OF ROCK2 INHIBITOR AND PREPARATION METHOD THEREFOR | ARNOLD, ERNST V | 1613 | §103DP | Non-Final OA | — | Pending | May 16, 2024 |
| 18691908 | SOLID FORM OF RHO-ASSOCIATED PROTEIN KINASE INHIBITOR OR SOLVATE THEREOF, PREPARATION METHOD AND USE THEREOF | MOU, LIYUAN | 1628 | §103§112DP | Non-Final OA | — | Pending | Mar 14, 2024 |
| 17607438 | METHOD FOR TREATING COUGH BY USING DIAMINOPYRIMIDINE COMPOUND | PECKHAM, RICHARD GRANT | 1627 | — | Final Rejection | — | Pending | Oct 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial